decisionhealth Newsletters, Answer Books - 2007 Issue 10 (October)
Answer_Book / Drugs_Injections / Coverage_for_off_label_chemotherapy_drugs
Subscribe or sign in to view the full article.
Article Overview
This article covers Medicare coverage of off-label anti-cancer drug use, including the role of medical compendia, peer-reviewed literature, and CMS guidance in evaluating whether a use is supported. It also addresses a clinical-trial billing scenario for colorectal cancer treatment and identifies which claims go to a carrier or DMERC. The content is relevant to coders, billers, oncology practices, and reimbursement staff who need to understand general coverage policy and claim submission context for these drugs.
Why This Topic Matters
Off-label oncology drug coverage can affect whether a claim is payable and where it should be submitted. The article helps readers understand the general documentation and coverage framework surrounding these services.
What You Will Learn
- How Medicare evaluates off-label anti-cancer drug coverage at a high level
- The role of medical compendia and peer-reviewed literature in coverage review
- The relationship between clinical trials and billing for certain oncology drugs
- Which administrative entities are referenced for claim submission in this context
Who Should Read This
- Medical coders
- Outpatient billers
- Oncology practice staff
- Revenue cycle specialists
- Compliance staff
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com